{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:11:49Z","timestamp":1793711509682,"version":"4.6.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004195","name":"Ocean University of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004195","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103983"],"award-info":[{"award-number":["82103983"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejmech.2025.117658","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T19:07:35Z","timestamp":1745262455000},"page":"117658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Discovery of hydrazide-based PI3K\/HDAC dual inhibitors with enhanced pro-apoptotic activity in lymphoma cells"],"prefix":"10.1016","volume":"292","author":[{"given":"Baogeng","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2106","authenticated-orcid":false,"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117658_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12935-021-02309-9","article-title":"Cytotoxicity of synthetic derivatives against breast cancer and multi-drug resistant breast cancer cell lines: a literature-based perspective study","volume":"21","author":"Sharmin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2025.117658_bib2","first-page":"7","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: a cancer journal for clinicians, Cancer statistics"},{"key":"10.1016\/j.ejmech.2025.117658_bib3","first-page":"17","article-title":"CA: a cancer journal for clinicians","volume":"73","author":"Siegel","year":"2023","journal-title":"Cancer statistics"},{"key":"10.1016\/j.ejmech.2025.117658_bib4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117658_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1242\/jcs.093773","article-title":"Classes of phosphoinositide 3-kinases at a glance","volume":"127","author":"Jean","year":"2014","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2025.117658_bib6","doi-asserted-by":"crossref","first-page":"re2","DOI":"10.1126\/scisignal.2002165","article-title":"Structural basis for activation and inhibition of class I phosphoinositide 3-kinases","volume":"4","author":"Vadas","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2025.117658_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1042\/BJ20111924","article-title":"Toxic prefibrillar \u03b1-synuclein amyloid oligomers adopt a distinctive antiparallel \u03b2-sheet structure","volume":"443","author":"Celej","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2025.117658_bib8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117658_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117658_bib10","doi-asserted-by":"crossref","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117658_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13578-020-00416-0","article-title":"Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours","volume":"10","author":"Xu","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ejmech.2025.117658_bib12","doi-asserted-by":"crossref","first-page":"10983","DOI":"10.1073\/pnas.211430998","article-title":"AKT plays a central role in tumorigenesis","volume":"98","author":"Testa","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.117658_bib13","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.3390\/cells11162508","article-title":"PI3K\/AKT\/mTOR-Targeted therapy for breast cancer","volume":"11","author":"Zhu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117658_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11912-019-0846-7","article-title":"PI3K inhibitors in breast cancer therapy","volume":"21","author":"Ellis","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2025.117658_bib15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117658_bib16","doi-asserted-by":"crossref","first-page":"35141","DOI":"10.18632\/oncotarget.26216","article-title":"Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines","volume":"9","author":"Namatame","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117658_bib17","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-13-B271","article-title":"Abstract: a first-in-human phase I study of ZSTK474, an oral pan-PI3K inhibitor, in patients with advanced solid malignancies","volume":"12","author":"Lockhart","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117658_bib18","doi-asserted-by":"crossref","first-page":"8568528","DOI":"10.1155\/2022\/8568528","article-title":"ZSTK474 sensitizes glioblastoma to temozolomide by blocking homologous recombination repair","author":"Jiao","year":"2022","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2025.117658_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117658_bib20","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s13238-020-00733-7","article-title":"Mapping the epigenetic modifications of DNA and RNA","volume":"11","author":"Zhao","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2025.117658_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17446651.2023.2183840","article-title":"HDACs as an emerging target in endocrine tumors: a comprehensive review","volume":"18","author":"Klieser","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.ejmech.2025.117658_bib22","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.ejmech.2025.117658_bib23","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/jcb.26476","article-title":"The mechanism and potential targets of class II HDACs in angiogenesis","volume":"119","author":"Hou","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2025.117658_bib24","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00018-012-0921-9","article-title":"Multiple roles of class I HDACs in proliferation, differentiation, and development","volume":"69","author":"Reichert","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.117658_bib25","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ejmech.2018.08.081","article-title":"HDAC3 is a potential validated target for cancer: an overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR\/QSAR\/QAAR approaches","volume":"157","author":"Adhikari","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117658_bib26","first-page":"203","article-title":"Clinical potential of novel therapeutic targets in breast cancer: CDK4\/6, Src, JAK\/STAT, PARP, HDAC, and PI3K\/AKT\/mTOR pathways","volume":"7","author":"Hosford","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.ejmech.2025.117658_bib27","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117658_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117658_bib29","doi-asserted-by":"crossref","first-page":"105182","DOI":"10.1016\/j.neuint.2021.105182","article-title":"Classical HDACs in the regulation of neuroinflammation","volume":"150","author":"Dai","year":"2021","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2025.117658_bib30","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117658_bib31","doi-asserted-by":"crossref","first-page":"113946","DOI":"10.1016\/j.ejmech.2021.113946","article-title":"Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)","volume":"227","author":"He","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117658_bib32","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/cancers11111794","article-title":"HDAC inhibitors in acute myeloid leukemia","volume":"11","author":"San Jos\u00e9-En\u00e9riz","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117658_bib33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117658_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/acs.jmedchem.1c01472","article-title":"Potent hydrazide-based HDAC inhibitors with a superior pharmacokinetic profile for efficient treatment of acute myeloid leukemia in vivo","volume":"65","author":"Jiang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117658_bib35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2025.117658_bib36","doi-asserted-by":"crossref","first-page":"110099","DOI":"10.1016\/j.cellsig.2021.110099","article-title":"PI3K\/NF-\u03baB-dependent TNF-\u03b1 and HDAC activities facilitate LPS-Induced RGS10 suppression in pulmonary macrophages","volume":"86","author":"Almutairi","year":"2021","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2025.117658_bib37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.soc.2013.06.008","article-title":"Targeting the PI3-kinase\/Akt\/mTOR signaling pathway","volume":"22","author":"Hassan","year":"2013","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.ejmech.2025.117658_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol Biomed"},{"key":"10.1016\/j.ejmech.2025.117658_bib39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117658_bib40","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/s41388-018-0550-3","article-title":"Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma","volume":"38","author":"Guo","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117658_bib41","doi-asserted-by":"crossref","first-page":"105734","DOI":"10.1016\/j.biocel.2020.105734","article-title":"Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: an emerging approach to overcome MSC-Induced resistance","volume":"122","author":"Mosleh","year":"2020","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117658_bib42","first-page":"93","article-title":"Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K\/mTOR inhibitor BEZ235 against glioblastoma","volume":"81","author":"Meng","year":"2019","journal-title":"Nagoya J. Med. Sci."},{"key":"10.1016\/j.ejmech.2025.117658_bib43","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jcmm.13935","article-title":"CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL","volume":"23","author":"Chen","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117658_bib44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41401-018-0108-5","article-title":"CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression","volume":"40","author":"F Fu","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.117658_bib45","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/cancers14041067","article-title":"Dual targeting of PI3K and HDAC by CUDC-907 inhibits pediatric neuroblastoma growth","volume":"14","author":"Chilamakuri","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117658_bib46","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","article-title":"A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy","volume":"81","author":"Fan","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117658_bib47","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1021\/acs.jmedchem.7b01465","article-title":"Design, synthesis, and preclinical evaluation of fused pyrimidine-based hydroxamates for the treatment of hepatocellular carcinoma","volume":"61","author":"Chen","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117658_bib48","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1021\/acs.jmedchem.9b00390","article-title":"Design, synthesis, and biological evaluation of 4-Methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-Kinases and histone deacetylases","volume":"62","author":"Zhang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117658_bib49","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1021\/acs.jmedchem.0c00193","article-title":"Design, synthesis, and biological evaluation of Quinazolin-4-one-Based hydroxamic acids as dual PI3K\/HDAC inhibitors","volume":"63","author":"Thakur","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117658_bib50","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/aps.2010.150","article-title":"ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system","volume":"31","author":"Kong","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.117658_bib51","doi-asserted-by":"crossref","first-page":"35141","DOI":"10.18632\/oncotarget.26216","article-title":"Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines","volume":"9","author":"Namatame","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117658_bib52","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1021\/jm200688y","article-title":"Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)","volume":"54","author":"Rewcastle","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117658_bib53","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3324\/haematol.2009.013870","article-title":"Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma","volume":"95","author":"Wozniak","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.117658_bib54","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.bbrc.2009.12.086","article-title":"Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib","volume":"391","author":"Ozaki","year":"2010","journal-title":"Biochem Bioph Res Co"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:09:12Z","timestamp":1762265352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425004234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":54,"alternative-id":["S0223523425004234"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117658","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of hydrazide-based PI3K\/HDAC dual inhibitors with enhanced pro-apoptotic activity in lymphoma cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117658"}}